The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response

@inproceedings{Biernacka2015TheIS,
  title={The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response},
  author={Joanna M. Biernacka and Katrin Sangkuhl and Gergory Jenkins and Ryan M. Whaley and Prabir Barman and Anthony J. Batzler and Russ B. Altman and Volker Arolt and J{\"u}rgen Brockm{\"o}ller and Chien Hao Chen and Katharina Domschke and Daniel K. Hall-Flavin and C J Hong and Ari Illi and Yuan Ji and Olli Kampman and Toshihiko Kinoshita and Eira Leinonen and Y J Liou and Taisei Mushiroda and Shinpei Nonen and Michelle K. Skime and L Wang and Berhard T Baune and Masaaki Kato and Y Lucy Liu and Verayuth Praphanphoj and Julia C. Stingl and Shih-Jen Tsai and Michiaki Kubo and Teri E. Klein and RichardM. Weinshilboum},
  booktitle={Translational Psychiatry},
  year={2015}
}
Response to treatment with selective serotonin reuptake inhibitors (SSRIs) varies considerably between patients. The International SSRI Pharmacogenomics Consortium (ISPC) was formed with the primary goal of identifying genetic variation that may contribute to response to SSRI treatment of major depressive disorder. A genome-wide association study of 4-week treatment outcomes, measured using the 17-item Hamilton Rating Scale for Depression (HRSD-17), was performed using data from 865 subjects… CONTINUE READING